Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 7/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26323603 | 0.91 | LTA4H (0.50) | ALDH1A1MAPK1L3MBTL1LTA4HSLC15A1 | |
| SCHEMBL6672089 | 0.89 | LTA4H (0.44) | ALDH1A1LTA4HSLC1A3SLC1A1KMT2A | |
| SCHEMBL27537171 | 0.88 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1SLC15A1SLC1A3 | |
| SCHEMBL27685709 | 0.87 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1LTA4HSLC15A1 | |
| SCHEMBL29113794 | 0.87 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1LTA4HSLC15A1 | |
| SCHEMBL6874313 | 0.85 | SLC15A1 (0.49) | ALDH1A1MAPK1L3MBTL1SLC15A1SLC1A3 | |
| SCHEMBL27622821 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL7391550 | 0.83 | LTA4H (0.48) | ALDH1A1MAPK1L3MBTL1LTA4HSLC15A1 | |
| SCHEMBL3985411 | 0.82 | SLC7A5 (0.56) | ALDH1A1MAPK1L3MBTL1LTA4HSLC15A1 | |
| SCHEMBL7272552 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1SLC15A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20050106120-A1 | Polyester containing active drugs and having amino acids in the main chain & comma; and its preparation method | CHENG SHUJUN (CN) | 2005-05-19 | — | — | US | disclosed |
| US-4935536-A | TRIALKOXYBENZYL PROTECTED AMINO ACID | MILLIPORE CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0292228-A2 | Protecting groups for asparagine and glutamine in peptide synthesis | MILLIPORE CORPORATION (US) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050106120-A1 | Polyester containing active drugs and having amino acids in the main chain & comma; and its preparation method | DAO, ADM2, ARG1 | ALDH1A1 806/4885MAPK1 1031/4885L3MBTL1 4395/4885 |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | ALDH1A1 4073/4885MAPK1 1877/4885L3MBTL1 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.